(2E,4E,6Z,8E)-3,7-dimethyl-8-((S)-4-methyl-3,4-dihydronaphthalen-1(2H)-ylidene)octa-2,4,6-trienoic acid

ID: ALA3098858

Chembl Id: CHEMBL3098858

PubChem CID: 73054431

Max Phase: Preclinical

Molecular Formula: C21H24O2

Molecular Weight: 308.42

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  CC(=C/C=C/C(C)=C/C(=O)O)/C=C1\CC[C@H](C)c2ccccc21

Standard InChI:  InChI=1S/C21H24O2/c1-15(7-6-8-16(2)14-21(22)23)13-18-12-11-17(3)19-9-4-5-10-20(18)19/h4-10,13-14,17H,11-12H2,1-3H3,(H,22,23)/b8-6+,15-7-,16-14+,18-13+/t17-/m0/s1

Standard InChI Key:  IUAWGSHMQSZQSY-KWACTLEVSA-N

Associated Targets(Human)

RARA Tclin Retinoic acid receptor alpha (1324 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
RXRA Tclin Retinoid X receptor alpha (3637 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Rattus norvegicus (775804 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Rxra Retinoid X receptor alpha (105 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 308.42Molecular Weight (Monoisotopic): 308.1776AlogP: 5.50#Rotatable Bonds: 4
Polar Surface Area: 37.30Molecular Species: ACIDHBA: 1HBD: 1
#RO5 Violations: 1HBA (Lipinski): 2HBD (Lipinski): 1#RO5 Violations (Lipinski): 1
CX Acidic pKa: 4.53CX Basic pKa: CX LogP: 5.29CX LogD: 2.50
Aromatic Rings: 1Heavy Atoms: 23QED Weighted: 0.59Np Likeness Score: 1.50

References

1. Desphande A, Xia G, Boerma LJ, Vines KK, Atigadda VR, Lobo-Ruppert S, Grubbs CJ, Moeinpour FL, Smith CD, Christov K, Brouillette WJ, Muccio DD..  (2014)  Methyl-substituted conformationally constrained rexinoid agonists for the retinoid X receptors demonstrate improved efficacy for cancer therapy and prevention.,  22  (1): [PMID:24359708] [10.1016/j.bmc.2013.11.039]

Source